<DOC>
	<DOCNO>NCT02647294</DOCNO>
	<brief_summary>Patients metabolic syndrome Nonalcoholic fatty liver disease ( NAFLD ) randomly allocate treatment n-3 PUFA ( 3.6 g/day ) placebo 12 month . At begin end study basic clinical anthropometric data , well parameter liver steatosis fibrosis test .</brief_summary>
	<brief_title>Polyunsaturated Fatty Acids Patients With NAFLD .</brief_title>
	<detailed_description>Patients metabolic syndrome Nonalcoholic fatty liver disease ( NAFLD ) randomly allocate treatment n-3 PUFA ( 3.6 g/day ) placebo 12 month . At begin end study basic clinical anthropometric data record follow parameter test : panel biochemistry liver function test : triglyceride , cholesterol , HDLcholesterol , LDL-cholesterol , glucose , insulin , serum bilirubin , liver test , thyroid hormone , bile acid metabolite , albumin , total protein . Bioactive metabolite , Inflammatory marker Non-invasive serum marker liver fibrosis steatohepatitis . Hyaluronic acid , NAFLD fibrosis score , cytokeratine-18 fragment . Ultrasonography non-invasive measurement fibrosis steatosis , magnetic resonance spectroscopy visceral liver fat determination .</detailed_description>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Patients metabolic syndrome NAFLD Age 18 year Gravidity Incompliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>